Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: Results from a single-arm, phase II study

Joshua Bauml, Tanguy Y. Seiwert, David G. Pfister, Francis Worden, Stephen V. Liu, Jill Gilbert, Nabil F. Saba, Jared Weiss, Lori Wirth, Ammar Sukari, Hyunseok Kang, Michael K. Gibson, Erminia Massarelli, Steven Powell, Amy Meister, Xinxin Shu, Jonathan D. Cheng, Robert Haddad